Functional Skills
Business Analysis
Business Development
Business Intelligence
Corporate Finance
Data Analysis
Data Strategy
Market Research
Market Intelligence
M&A Support
M&A Deal Sourcing
Strategic Planning
Strategy Development
Venture Capital Investing
Software Skills
Microsoft Excel
Microsoft PowerPoint
Data visualization
Sector Experience
Healthcare
Life Sciences & Pharma
Manufacturing
Technology
Notable Clients
BCG
Ernst & Young (EY)
McKinsey & Company
Roland Berger Strategy Consultants
ZS
Fortune 500
Experience
Self-employed
Management Consulting
Advisory Pharmaceutical Consultancy
7/2022 - Present
Leveraging expertise in CDMO, Auto-immune & Neurology, providing ongoing consultations with blue chip clients including E&Y, Mckinsey and investment banks.
● ¨ Strategy & Outsourcing insight
• Decision optimisation at the corporate level; European Mid-cap R&D strategy, in-licensing, M&A rationale and company valuation.
• Trends in Blow-Fill Seal manufacturing; opportunities and competitive environment; Market opportunity for high potent API manufacturing; Overarching trends in the CDMO sector, drivers, market dynamics & ROI by modality.
¨ Therapeutics including
• CNS drug development & commercialisation; challenges across multiple diseases & best practice; Current epilepsy landscape, the transition to rare disease and the emergence of the digital ecosystem; Rare neurological diseases; from clinical requirements to best commercial practice.
• FcRN landscape, pre-clinical biology, strategic implications and dynamics; Utility of Targeted protein degradation in haematological cancers; landscape
● ¨ Strategy & Outsourcing insight
• Decision optimisation at the corporate level; European Mid-cap R&D strategy, in-licensing, M&A rationale and company valuation.
• Trends in Blow-Fill Seal manufacturing; opportunities and competitive environment; Market opportunity for high potent API manufacturing; Overarching trends in the CDMO sector, drivers, market dynamics & ROI by modality.
¨ Therapeutics including
• CNS drug development & commercialisation; challenges across multiple diseases & best practice; Current epilepsy landscape, the transition to rare disease and the emergence of the digital ecosystem; Rare neurological diseases; from clinical requirements to best commercial practice.
• FcRN landscape, pre-clinical biology, strategic implications and dynamics; Utility of Targeted protein degradation in haematological cancers; landscape
UCB
Corporate Strategy & Development
Director R&D Neurology, Insights
11/2019 - 1/2022
Corporate Development and Finance. Challenger function, neuroscience expert providing Governance support to ExCom.
UCB
Corporate Strategy & Development
Neurology Insights Lead
6/2018 - 11/2019
Built competitor intelligence function at European Biopharmaceutical company with a focus on neurodegeneration and Auto-immune disorders
GlobalData (London), PharmSource
Corporate Strategy & Development
Director Market Intelligence
6/2012 - 6/2018
Strategic Advantage Database, Industry Trend Reports, Lead Sheet Strategy, and Editor. Builder of boutique consultancy to global CDMO sector.
Abbott Laboratories
Corporate Strategy & Development
Decision Support Manager Strategy and Corporate Development
10/2007 - 6/2012
Data analytics, sales support
PharmSource
Research
Consultant
7/2007 - 9/2007
Opportunity sizing for High Potent API chemicals market
Cardinal Health
Corporate Strategy & Development
Senior Manager, Strategic Intelligence
3/1999 - 7/2007
Corporate and business analysis in $2bn division:corporate and strategic planning, M&A, in-licensing.
Corporate and Business Development, Competitive Intelligence Senior Manager, Business Intelligence Europe $750m European division.
Corporate and Business Development, Competitive Intelligence Senior Manager, Business Intelligence Europe $750m European division.